Core Insights - OneMedNet Corporation has received strong validation for its redesigned data exploration and cohort-building platform from customers and prospects at ISPOR Europe, showcasing its commercial relevance and competitive differentiation [2][3] - The platform, built on Palantir Foundry and AIP, allows research teams to determine cohort feasibility in minutes instead of weeks, enhancing accuracy and efficiency [3][4] Company Overview - OneMedNet operates the largest global live, regulatory-grade AI-ready Real-World Data (RWD) network, encompassing over 2,130 provider sites, 47+ million unique patient lives, and 186+ million clinical exams and images [2][4] - The company aims to revolutionize the use of Real-World Data, providing insights that drive innovation in drug development, medical devices, and AI applications [4][5] Technological Advancements - Key advancements of the new platform include significantly faster cohort feasibility, AI-driven natural-language search for complex discovery tasks, and real-time availability of longitudinal insights [7] - The platform supports subscription workflows, which is expected to contribute to recurring-revenue growth for the company [7]

Core Insights - OneMedNet Corporation reported significant financial and operational progress in Q3 2025, highlighting a strong sales pipeline and increased demand for its AI-powered Real-World Data solutions [1][4]. Financial Highlights - Bookings reached $1.1 million in Q3 2025, representing an 815% increase compared to Q3 2024 [8]. - The company successfully completed an additional $0.5 million private placement of common stock, enhancing its strategic investment capabilities [8]. - OneMedNet improved its balance sheet by reducing total liabilities by $1.9 million in Q3, with a total reduction of $14.3 million year-to-date [8]. Operational Highlights - The integration of Palantir's AI Platform commenced in September 2025, enhancing the iRWD™ network with capabilities such as faster data discovery, AI-driven de-identification, and multimodal data integration [8]. - The rollout of a SaaS subscription model was announced, featuring Live Data Feeds and AI-Driven Conversational Search, transforming static data access into dynamic, on-demand intelligence [8]. - The company emphasized its focus on strategic opportunities to deliver long-term value, resulting in a 4.5X increase in inbound demand and larger deal sizes [4].

Core Insights - OneMedNet Corporation is set to showcase its next-generation iRWD™ platform at ISPOR Europe, which leverages the Palantir Technologies Foundry ecosystem to provide secure, regulatory-grade real-world data (RWD) through advanced AI analytics [1][3] - The company has introduced a recurring revenue model that enhances customer access to high-value RWD, featuring Live Data Feeds and AI-Driven Conversational Search, transforming static data access into dynamic, on-demand intelligence [2][7] - The healthcare sector is projected to present an estimated US$868 billion opportunity by 2030, with a significant challenge being the acquisition of high-quality, de-identified clinical multimodal data [3] Company Developments - OneMedNet's iRWD™ platform is designed to revolutionize the access and operationalization of real-world data from over 1,750 healthcare sites, providing insights that can drive innovation in drug development and patient care [4] - The platform's Live Data Feeds offer real-time streams of de-identified clinical data, while the AI-Driven Conversational Search allows users to query complex datasets using natural language, enhancing data accessibility and reducing technical barriers [7] Market Context - The AI-enabled market within healthcare is at a transformative inflection point, with responsible access to healthcare data being a key barrier to unlocking its full potential [3] - OneMedNet's collaboration with Palantir is expected to enhance its capabilities in delivering regulatory-grade, multimodal RWD with improved speed, consistency, and security [3]

Core Insights - HEALWELL AI's DARWEN™ AI Platform is one of the first to generate regulatory-grade real-world data (RWD) to enhance patient access and advance the pharmaceutical industry [3][4][6] - The collaboration with Takeda Pharmaceutical showcased the platform's ability to improve remission outcomes in ulcerative colitis and Crohn's disease through vedolizumab dose escalation [4][6] - HEALWELL's unique AI-driven RWD generation capability is expected to significantly impact clinical and commercial value in healthcare [3][6] Company Overview - HEALWELL AI Inc. focuses on preventative care using artificial intelligence to improve healthcare outcomes through early disease detection [9] - The company is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under "HWAIF" [9] - HEALWELL has been recognized for its leadership in healthcare AI, being named a finalist in Newsweek's AI Impact Awards 2025 [7][8] Industry Impact - The use of AI in generating RWD is a transformative approach that can lead to more precise and effective patient-centered care [5][6] - The platform's ability to extract clinically meaningful insights from electronic health records positions HEALWELL at the forefront of healthcare AI innovation [5][6] - The advancements in RWD generation are expected to facilitate faster and more accurate development of pharmaceutical products, ultimately improving patient outcomes [5][6]

Core Insights - OneMedNet Corporation has been selected by mlHealth360 as its Real-World Data provider, marking a significant milestone in the expansion of OneMedNet's subscription-based business model [1][2][3] Company Overview - OneMedNet is a leader in AI-powered Real-World Data (RWD), utilizing data from over 1,750 healthcare provider sites and 131 million+ clinical studies to support healthcare innovation [1][4] - The company’s iRWD™ platform provides regulatory-grade, de-identified imaging and clinical data, which is crucial for AI model development and validation [2][4] Partnership Details - The multi-year agreement with mlHealth360 allows continuous access to curated X-Ray and CT datasets, enhancing mlHealth360's capabilities in medical imaging [2][3] - The collaboration aims to improve patient care by providing high-quality medical imaging data, which is essential for advancing AI model development [3][6] Market Demand - There is a growing market demand for high-quality, multimodal Real-World Data that supports model training and regulatory-grade validation, highlighting the importance of partnerships with AI and analytics companies [3][4]

Core Insights - OneMedNet Corporation reported significant improvements in its financial results for Q2 2025, highlighting a stronger balance sheet and operational advancements [1][4]. Financial Highlights - Total liabilities decreased from $19.7 million as of December 31, 2024, to $6.2 million as of June 30, 2025, marking a reduction of approximately $13.5 million, or about 80% [8]. - The company achieved net income of $3.0 million for Q2 2025, with other income of $5.0 million attributed to discounted debt settlements and conversions [8]. - OneMedNet successfully completed $3.7 million in private placements, including $1.2 million from insiders, to support sales execution and platform expansion [8]. Operational Highlights - The company expanded its provider network to 1,750 healthcare sites, now offering access to 136 million clinical studies [8]. - OneMedNet enhanced its iRWD™ platform capabilities, improving AI-driven de-identification, federated search, and multi-modal data integration [8]. - The company maintains a strategic digital asset position of 15 BTC valued at $1.6 million as of June 30, 2025 [8]. Strategic Focus - OneMedNet is committed to leveraging its improved balance sheet and strong sales funnel to pursue strategic opportunities that deliver long-term value to customers, partners, and shareholders [4]. - The company aims to revolutionize the use of Real-World Data (RWD) across various industries, including healthcare, finance, retail, and telecom, by harnessing the potential of its iRWD™ platform [5][6].

Core Viewpoint - OneMedNet Corporation has successfully raised approximately $3.7 million through private placement transactions at a price of $0.42 per share, with participation from the company's founders and directors [1][2]. Financial Actions - The proceeds from the private placements will be utilized for working capital and general corporate purposes [2]. - The company has achieved a 60% reduction in total liabilities, settling or converting approximately $11.0 million of current liabilities as of March 31, 2025 [3]. - Specific financial actions include settling approximately $3.26 million of deferred underwriter fees, $1.08 million in trade payables, and converting $6.56 million of principal and interest into common stock [8]. Company Overview - OneMedNet is a leader in providing regulatory-grade imaging Real-World Data (iRWD), leveraging data from over 1,400 healthcare sites to drive innovation in healthcare [6]. - The company’s iRWD™ platform supports advancements in various medical fields, including rare diseases, oncology, and cardiology, by delivering precision insights [6]. - Beyond healthcare, OneMedNet's proprietary AI technology anonymizes data for other industries such as finance, retail, and telecom, enhancing data security and project de-risking [7].